Ipsen: new data in neuroendocrine tumors

(CercleFinance.com) - On Wednesday Ipsen unveiled new quantitative data for patients and healthcare professionals' experience in the treatment of neuroendocrine tumors (NETs) and acromegaly.


The pharmaceutical group says that these results - presented at the annual conference of the European Neuroendocrine Tumor Society (ENETS), which is currently being held "virtually" due to the coronavirus epidemic - support its "personal" approach towards patients.

In particular, these studies are aimed at assessing patients and nurses' level of satisfaction with the use of their new Somatuline Autogel syringe compared to the previous version.

Ipsen said that they also measure the level of satisfaction of patients who administer the drug themselves with the laboratory's new syringe.


Copyright (c) 2020 CercleFinance.com. All rights reserved.